EyePoint Pharmaceuticals Inc has a consensus price target of $35.22, established from looking at the 33 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Baird, and Chardan Capital on May 13, 2024, May 8, 2024, and May 7, 2024. With an average price target of $32 between HC Wainwright & Co., Baird, and Chardan Capital, there's an implied 157.44% upside for EyePoint Pharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/13/2024 | Buy Now | 141.35% | HC Wainwright & Co. | Yi Chen | $33 → $30 | Maintains | Buy | Get Alert |
05/08/2024 | Buy Now | 205.71% | Baird | — | $46 → $38 | Maintains | Outperform | Get Alert |
05/07/2024 | Buy Now | 125.26% | Chardan Capital | Daniil Gataulin | $39 → $28 | Maintains | Buy | Get Alert |
05/07/2024 | Buy Now | 141.35% | Mizuho | Graig Suvannavejh | $39 → $30 | Maintains | Buy | Get Alert |
03/08/2024 | Buy Now | 165.49% | HC Wainwright & Co. | Yi Chen | $33 → $33 | Maintains | Buy | Get Alert |
02/16/2024 | Buy Now | 213.76% | Mizuho | Graig Suvannavejh | $30 → $39 | Maintains | Buy | Get Alert |
01/22/2024 | Buy Now | 181.58% | JP Morgan | Tessa Romero | → $35 | Initiates | → Overweight | Get Alert |
01/16/2024 | Buy Now | 165.49% | HC Wainwright & Co. | Yi Chen | $35 → $33 | Maintains | Buy | Get Alert |
12/11/2023 | Buy Now | 253.98% | Capital One | Zegbeh Jallah | → $44 | Initiates | → Overweight | Get Alert |
12/07/2023 | Buy Now | 141.35% | Mizuho | Graig Suvannavejh | $20 → $30 | Maintains | Buy | Get Alert |
12/05/2023 | Buy Now | 181.58% | HC Wainwright & Co. | Yi Chen | $25 → $35 | Maintains | Buy | Get Alert |
11/02/2023 | Buy Now | 101.13% | HC Wainwright & Co. | Yi Chen | $27 → $25 | Maintains | Buy | Get Alert |
11/02/2023 | Buy Now | 60.9% | Mizuho | Graig Suvannavejh | → $20 | Initiates | → Buy | Get Alert |
09/14/2023 | Buy Now | 149.4% | Cantor Fitzgerald | Jennifer Kim | → $31 | Reiterates | Overweight → Overweight | Get Alert |
09/12/2023 | Buy Now | 117.22% | HC Wainwright & Co. | Yi Chen | → $27 | Reiterates | Buy → Buy | Get Alert |
08/31/2023 | Buy Now | 149.4% | Cantor Fitzgerald | Jennifer Kim | → $31 | Reiterates | Overweight → Overweight | Get Alert |
08/03/2023 | Buy Now | 117.22% | HC Wainwright & Co. | Yi Chen | → $27 | Reiterates | Buy → Buy | Get Alert |
08/03/2023 | Buy Now | 76.99% | Chardan Capital | Daniil Gataulin | → $22 | Reiterates | Buy → Buy | Get Alert |
07/28/2023 | Buy Now | 117.22% | HC Wainwright & Co. | Yi Chen | → $27 | Reiterates | Buy → Buy | Get Alert |
06/28/2023 | Buy Now | 149.4% | Cantor Fitzgerald | Jennifer Kim | → $31 | Reiterates | Overweight → Overweight | Get Alert |
06/14/2023 | Buy Now | 109.17% | JonesTrading | Sean Kim | → $26 | Initiates | → Buy | Get Alert |
06/06/2023 | Buy Now | 117.22% | HC Wainwright & Co. | Yi Chen | → $27 | Reiterates | Buy → Buy | Get Alert |
05/19/2023 | Buy Now | 117.22% | HC Wainwright & Co. | Yi Chen | $25 → $27 | Maintains | Buy | Get Alert |
05/19/2023 | Buy Now | 76.99% | Chardan Capital | Daniil Gataulin | $21 → $22 | Maintains | Buy | Get Alert |
05/18/2023 | Buy Now | 342.48% | Guggenheim | Yatin Suneja | $52 → $55 | Maintains | Buy | Get Alert |
03/27/2023 | Buy Now | 101.13% | HC Wainwright & Co. | Yi Chen | → $25 | Reiterates | → Buy | Get Alert |
03/03/2023 | Buy Now | 68.95% | Chardan Capital | Daniil Gataulin | → $21 | Reiterates | → Buy | Get Alert |
03/03/2023 | Buy Now | 101.13% | HC Wainwright & Co. | Yi Chen | → $25 | Reiterates | → Buy | Get Alert |
02/28/2023 | Buy Now | 101.13% | HC Wainwright & Co. | Yi Chen | → $25 | Reiterates | → Buy | Get Alert |
11/11/2022 | Buy Now | 318.34% | Guggenheim | Yatin Suneja | $60 → $52 | Maintains | Buy | Get Alert |
The latest price target for EyePoint Pharmaceuticals (NASDAQ: EYPT) was reported by HC Wainwright & Co. on May 13, 2024. The analyst firm set a price target for $30.00 expecting EYPT to rise to within 12 months (a possible 141.35% upside). 24 analyst firms have reported ratings in the last year.
The latest analyst rating for EyePoint Pharmaceuticals (NASDAQ: EYPT) was provided by HC Wainwright & Co., and EyePoint Pharmaceuticals maintained their buy rating.
There is no last upgrade for EyePoint Pharmaceuticals.
There is no last downgrade for EyePoint Pharmaceuticals.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of EyePoint Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for EyePoint Pharmaceuticals was filed on May 13, 2024 so you should expect the next rating to be made available sometime around May 13, 2025.
While ratings are subjective and will change, the latest EyePoint Pharmaceuticals (EYPT) rating was a maintained with a price target of $33.00 to $30.00. The current price EyePoint Pharmaceuticals (EYPT) is trading at is $12.43, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.